Form 4: BioLife Solutions Director Rachel Ellingson Reports Acquisition of Common Stock
SEC Form 4 Filing
Director Rachel Ellingson reports acquiring 11,264 shares of BioLife Solutions common stock on March 8, 2024.
Summary
- Rachel Ellingson, a director at BioLife Solutions Inc., filed a Form 4 on March 12, 2024, reporting a transaction.
- On March 8, 2024, Ellingson acquired 11,264 shares of common stock.
- The shares were acquired under the BioLife Solutions 2023 Performance Incentive Plan.
- Following the transaction, Ellingson beneficially owns 42,949 shares of BioLife Solutions Inc.
- The restricted stock vests fully on the first anniversary of the grant date.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it's a standard regulatory filing. The director's stock acquisition is a mildly positive signal.
Positives
- A director's acquisition of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Future Outlook
The document does not contain any specific forward-looking statements.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/08/2024 | Date of transaction: Rachel Ellingson acquired 11,264 shares of common stock. |
| 03/12/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.